Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical study

27 Sept 2024

Abstract excerpt

Immunotherapeutic drugs are promising medicines for cancer treatment. A potential candidate for immunotherapy is interleukin-12 (IL-12), a cytokine well known for its ability to mediate antitumor activity. We developed a plasmid encoding human IL-12 devoid of an antibiotic resistance gene (phIL12). For the approval of phase I clinical trials in basal cell carcinoma (BCC), the regulatory agency requires...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Viral gastroenteritis research and epidemiology
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39333733
DOI: 10.1038/s41598-024-73314-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical studyPMID 39333733Read ↗

Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck regionSemantic proximity Read ↗

Gene Therapy of Cancer Based on Interleukin 12Semantic proximity Read ↗

Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumorsSemantic proximity Read ↗

Plasmid BiopharmaceuticalsSemantic proximity Read ↗

Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model.Semantic proximity Read ↗

Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regsSemantic proximity Read ↗

Systemically targeted cancer immunotherapy and gene delivery using transmorphic particlesSemantic proximity Read ↗

Optimization of the Tet-on System To Regulate Interleukin 12 Expression in the Liver for the Treatment of Hepatic TumorsSemantic proximity Read ↗

Designing and Development of a DNA Vaccine Expressing HER2/ HER3 and CCL20 as a Novel Candidate for Breast Cancer VaccineSemantic proximity Read ↗

504 Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 studySemantic proximity Read ↗

Anti-tumor effect of IL-2 and TRAIL expressed by recombinant Salmonella: an immunotherapeutic proposal against bladder cancer by iNOS, Caspases activation and modulation of the immune systemSemantic proximity Read ↗

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.